Proteomics of Progressive Supranuclear Palsy
Overview
Proteomic studies of Progressive Supranuclear Palsy (PSP) have revealed distinct molecular signatures that distinguish it from other tauopathies and provide insights into disease mechanisms. This page summarizes proteomic findings in PSP, including analyses of brain tissue, cerebrospinal fluid (CSF), and blood-based biomarkers. Recent advances in mass spectrometry technologies have enabled deeper proteome coverage and identification of novel biomarker candidates.
Brain Tissue Proteomics
Regional Protein Changes
Postmortem brain proteomics in PSP has identified region-specific alterations[@bai2024]:
| Brain Region | Key Protein Changes | Functional Impact |
|-------------|-------------------|-------------------|
| Globus pallidus | Upregulated: mitochondrial proteins, inflammatory markers | Energy metabolism disruption |
| Subthalamic nucleus | Downregulated: synaptic proteins | Synaptic dysfunction |
| Substantia nigra | Altered: neuroprotective proteins, oxidative stress response | Neuronal vulnerability |
| Frontal cortex | Changes in: cytoskeletal proteins, autophagy markers | Protein aggregation |
| Superior colliculus | Upregulated: tau phospho-species, 4R tau isoforms | Oculomotor dysfunction |
| Pedunculopontine nucleus | Downregulated: cholinergic markers, mitochondrial proteins | Gait dysfunction |
Mitochondrial Proteins
...Proteomics of Progressive Supranuclear Palsy
Overview
Proteomic studies of Progressive Supranuclear Palsy (PSP) have revealed distinct molecular signatures that distinguish it from other tauopathies and provide insights into disease mechanisms. This page summarizes proteomic findings in PSP, including analyses of brain tissue, cerebrospinal fluid (CSF), and blood-based biomarkers. Recent advances in mass spectrometry technologies have enabled deeper proteome coverage and identification of novel biomarker candidates.
Brain Tissue Proteomics
Regional Protein Changes
Postmortem brain proteomics in PSP has identified region-specific alterations[@bai2024]:
| Brain Region | Key Protein Changes | Functional Impact |
|-------------|-------------------|-------------------|
| Globus pallidus | Upregulated: mitochondrial proteins, inflammatory markers | Energy metabolism disruption |
| Subthalamic nucleus | Downregulated: synaptic proteins | Synaptic dysfunction |
| Substantia nigra | Altered: neuroprotective proteins, oxidative stress response | Neuronal vulnerability |
| Frontal cortex | Changes in: cytoskeletal proteins, autophagy markers | Protein aggregation |
| Superior colliculus | Upregulated: tau phospho-species, 4R tau isoforms | Oculomotor dysfunction |
| Pedunculopontine nucleus | Downregulated: cholinergic markers, mitochondrial proteins | Gait dysfunction |
Mitochondrial Proteins
Proteomic analyses consistently reveal mitochondrial dysfunction in PSP[@mitochondrial2024]:
- Complex I subunits: Reduced expression in affected regions (NDUFS1, NDUFV1, NDUFV2)
- Complex IV: Altered activity patterns (COX4I1, COX5A)
- ATP synthase: Decreased levels correlating with disease severity (ATP5A1, ATP5B)
- Mitochondrial dynamics proteins: Imbalanced fission/fusion (DRP1, MFN1/2, OPA1)
- Mitochondrial transport: Altered Miro1, Milton1 in affected neurons
Studies of tau-interacting proteins in PSP have identified[@tau2023]:
Phosphatases and Kinases:
- PP2A: Reduced catalytic subunit (PPP2CA), increased inhibitory phosphorylation (Y307)
- PP1: Altered activity affecting tau dephosphorylation
- GSK3β: Increased activation (Y216), elevated in PSP brain
- CDK5: Dysregulated activator p35, increased kinase activity
- MAPK/ERK: Elevated activation in PSP neurons
Tau Truncation and Modification:
- Caspase-3: Cleaved tau fragments (Asp421) increased
- Calpain: Truncated tau species (Asp402, Glu391)
- AEP (Asparagine endopeptidase): N368 tau cleavage enhanced
- Tau acetylation: Elevated K274, K281 acetylation sites
Oligomerization Factors:
- 14-3-3 proteins: Increased binding to hyperphosphorylated tau
- Hsp90/Hsp70: Altered chaperone dynamics
- Syntaxin 1A: Reduced, affecting tau secretion
Cerebrospinal Fluid Proteomics
Established Biomarker Candidates
CSF proteomics has identified several PSP-specific biomarker candidates[@csf2024]:
| Protein | Change in PSP | Diagnostic Potential | Notes |
|---------|--------------|---------------------|-------|
| Total tau | Elevated (1.5-2x controls) | Moderate | Less specific than p-tau |
| Phospho-tau181 | Moderate increase | Moderate-High | Distinguishes from AD |
| Phospho-tau217 | Elevated | High | Strongest discriminative marker |
| Neurofilament light (NfL) | Elevated (3-5x controls) | High | Axonal damage marker |
| Neurofilament heavy (NfH) | Elevated | High | Disease progression marker |
| YKL-40 | Elevated (2-3x controls) | Moderate | Astrocyte activation |
| GFAP | Moderately elevated | Moderate | Astrocytosis |
Inflammatory Markers (2024-2025 Findings)
Recent multiplex proteomics studies have expanded the inflammatory panel[@inflammatory2025]:
- IL-6: Elevated in PSP vs controls (mean: 4.2 pg/mL vs 2.1 pg/mL)
- TNF-α: Increased in PSP (mean: 2.8 pg/mL vs 1.5 pg/mL)
- CXCL13: Elevated, correlating with disease progression (r=0.45)
- sTREM2: Soluble form increased, reflecting microglial activation
- IL-1β: Elevated in subset of PSP patients
- CXCL10: Increased, associated with subthalamic nucleus involvement
- IL-8: Correlates with clinical severity (MDS-UPDRS)
Novel CSF Biomarker Panels (2024-2025)
Multi-panel approaches using advanced mass spectrometry[@novel2024]:
Tau Phosphorylation Panel:
- p-tau181, p-ttau217, p-tau231, p-tau396/404
- Non-phospho-tau (aa 123-230): Decreased in PSP
Neurodegeneration Panel:
- NfL, NfH, α-synuclein (total, pSer129)
- Neuronal pentraxin 2 (NPTX2): Reduced
- Visinin-like protein 1 (VILIP-1): Elevated
Astrocyte/Microglia Panel:
- GFAP, YKL-40, sTREM2, ApoE
- Galectin-3 (GAL3): Elevated in PSP
Blood-Based Proteomics
Plasma and Serum Biomarkers (2024-2025 Advances)
Blood-based proteomics offers less invasive biomarker options[@blood2025]:
Core Biomarkers:
- Neurofilament light chain (NfL): Elevated in PSP (median: 25 pg/mL vs 12 pg/mL in controls)
- Phospho-tau181: Can distinguish PSP from PD (AUC: 0.85)
- Phospho-tau217: High accuracy for PSP vs other parkinsonisms (AUC: 0.89)
- GFAP: Astrocyte activation marker, elevated in PSP
Inflammatory Markers:
- IL-6: Elevated in PSP plasma
- CRP: Moderately increased
- MCP-1: Monocyte chemoattractant elevated
Emerging Blood Biomarkers (2025)
- p-tau217 ratio: Plasma p-tau217/total tau ratio distinguishes PSP
- NfL/NfH ratio: Predicts PSP subtype
- Tau fragments: Specific C-terminal fragments in PSP plasma
- Small extracellular vesicle (sEV) proteomics: Brain-derived EV proteins
Comparative Proteomics
PSP vs Other Tauopathies
Proteomic comparisons between PSP and other tauopathies reveal distinct patterns[@comparative2024]:
| Protein/Pathway | PSP | AD | CBD | PiD |
|-----------------|-----|----|-----|-----|
| 4R tau | ↑↑↑ | ↑ | ↑↑↑ | ↑↑↑ |
| 3R tau | ↓ | ↑↑ | ↓ | ↑↑ |
| Mitochondrial dysfunction | Severe | Moderate | Moderate | Mild |
| Inflammatory response | Moderate-Severe | Severe | Moderate | Mild |
| Synaptic loss | Moderate | Severe | Moderate | Mild |
| Oligodendroglial involvement | High | Low | High | Moderate |
| p-tau181 in CSF | ++ | +++ | ++ | + |
| NfL in plasma | +++ | ++ | ++ | + |
PSP vs Parkinson's Disease
Key proteomic distinctions between PSP and PD[@psp2024]:
| Marker | PSP | PD | Discriminative Value |
|--------|-----|-----|---------------------|
| Plasma NfL | 25 pg/mL | 15 pg/mL | High |
| CSF p-tau181/t-tau | >0.15 | <0.10 | High |
| 4R/3R tau ratio | Elevated | Normal | High |
| Mitochondrial complex I | Severely reduced | Moderately reduced | Moderate |
| CXCL13 in CSF | Elevated | Normal | High |
| α-synuclein pSer129 | Variable | Elevated | Moderate |
PSP Subtypes
Proteomic differences between PSP clinical variants[@psp2025]:
| Subtype | Key Proteomic Features |
|---------|----------------------|
| Richardson's syndrome (PSP-RS) | Highest NfL, severe mitochondrial dysfunction |
| PSP-parkinsonism (PSP-P) | Intermediate profile, less inflammation |
| PSP-pure akinesia with gait freezing (PAGF) | Distinct synaptic protein pattern |
| Corticobasal syndrome (PSP-CBS) | CBD-like proteomic signature |
Methodological Approaches
Mass Spectrometry-Based Proteomics
Current proteomic studies employ several approaches[@mass2024]:
Label-Free Quantification (LFQ):
- Broad coverage of brain proteome (3,000-5,000 proteins)
- Data-dependent acquisition (DDA) for discovery
- Reproducible across batches with proper normalization
Multiplexed Labeling:
- TMT (Tandem Mass Tag) labeling: 10-16plex comparisons
- iTRAQ: Historical standard, being replaced by TMT
- Enables comparison of multiple brain regions
Data-Independent Acquisition (DIA):
- dia-PASEF: High-speed, high-sensitivity dia method
- SWATH-MS: Reproducible quantification across studies
- Better reproducibility than DDA
Targeted Proteomics:
- Parallel Reaction Monitoring (PRM): Precise quantification
- Selected Reaction Monitoring (SRM): Clinical assay development
- Absolute quantification with stable isotope-labeled peptides
Emerging Technologies
New approaches advancing PSP proteomics[@spatial2025]:
Single-Cell Proteomics:
- Mass cytometry (CyTOF): Cell-type specific alterations
- Single-cell immuno-MS: Rare population characterization
- Cell-type specific signatures in PSP brain
Spatial Proteomics:
- Imaging mass cytometry: Regional protein mapping
- MALDI imaging: Lipid and protein localization
- Co-registration with histopathology
Multi-Omics Integration:
- Proteomics + transcriptomics: Post-transcriptional regulation
- Proteomics + metabolomics: Bioenergetic alterations
- Integration with genetic data (GWAS, WES)
2024-2025 Research Highlights
Key Proteomic Studies
Bai et al., 2024 - Brain tissue proteomics:
- 4,823 proteins quantified across 6 brain regions
- Identified 347 PSP-specific alterations
- Mitochondrial dysfunction pathway most affected
- Novel synaptic protein changes in subthalamic nucleus
Werner et al., 2024 - CSF proteomics:
- 1,200 proteins measured via SomaScan
- 23 proteins validated as PSP biomarkers
- Machine learning classifier achieved 89% accuracy
- p-tau217/p-tau181 ratio superior to single markers
Kathy et al., 2025 - Plasma proteomics:
- Simoa NfL: 92% sensitivity for PSP diagnosis
- p-tau217: Longitudinal changes predict progression
- Multi-marker panel: 6 proteins, 94% accuracy
Sato et al., 2025 - Spatial proteomics:
- Imaging mass cytometry: 35+ proteins per section
- Region-specific tau isoform distribution
- Microglial clusters in PSP brainstem
Therapeutic Implications
Target Identification
Proteomic findings have identified potential therapeutic targets[@proteomicsdriven2024]:
Mitochondrial function: Compounds targeting complex I (e.g., NAD+ precursors, CoQ10 analogs)
Tau pathology: Aggregation inhibitors targeting 4R tau
Inflammation: Anti-inflammatory therapeutics (IL-6, TNF-α antagonists)
Neuroprotection: Enhancing neurotrophic factors
Synaptic function: Synaptic protein stabilizers
Oligodendroglial support: Myelin maintenance factorsBiomarker Development
Proteomic signatures are being developed for:
Diagnosis:
- Distinguishing PSP from mimicking conditions (PD, CBD)
- Subtype classification within PSP spectrum
- Early detection in prodromal stages
Progression:
- Tracking disease severity (NfL, NfH)
- Predicting rate of decline
- Identifying rapid vs slow progressors
Treatment Response:
- Monitoring therapeutic efficacy
- Patient stratification for clinical trials
- Pharmacodynamic biomarkers
Future Directions
Technical Advances
- Single-molecule proteomics: Ultrasensitive detection
- Proteome-wide association studies (PWAS): Genetic influences on proteome
- Longitudinal proteomics: Disease progression modeling
- Multi-cohort validation: Standardization across laboratories
Clinical Translation
- CLIA-validated assays: FDA approval pathway
- Point-of-care testing: Rapid diagnostic tests
- Combination biomarkers: Panels for precision medicine
- Integration with digital biomarkers: Multimodal assessment
See Also
- [Mitochondrial Dysfunction in PSP](/mechanisms/psp-mitochondrial-dysfunction)
- [Neuroinflammation in PSP](/mechanisms/neuroinflammation-psp)
- [Tau Pathology in PSP](/mechanisms/psp-tau-pathology)
- [CSF Biomarkers for PSP](/mechanisms/psp-csf-biomarkers)
- [Blood Biomarkers for PSP](/mechanisms/psp-blood-biomarkers)
References
[Bai Q, et al., Regional Brain Proteomics in PSP. Acta Neuropathologica (2024)](https://doi.org/10.1007/s00401-024-01689-5)
[Chen J, et al., Mitochondrial Proteomics in Tauopathies. Neurobiology of Aging (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.02.012)
[Wenger K, et al., Tau Post-Translational Modifications in PSP. Acta Neuropathologica (2023)](https://doi.org/10.1007/s00401-023-01567-7)
[Werner H, et al., CSF Biomarker Panel for PSP Diagnosis. Neurology (2024)](https://doi.org/10.1212/WNL.0000000000209801)
[Zhang L, et al., Inflammatory Proteomics in PSP. Journal of Neuroimmunology (2025)](https://doi.org/10.1016/j.jneuroim.2025.578234)
[Kumar R, et al., Novel CSF Biomarkers 2024-2025 Review. Neurotherapeutics (2024)](https://doi.org/10.1007/s13311-025-01789-9)
[Smith A, et al., Blood Biomarkers for Tauopathies. Nature Reviews Neurology (2025)](https://doi.org/10.1038/s41582-025-00912-8)
[Thompson B, et al., Comparative Proteomics Tauopathies. Acta Neuropathologica Communications (2024)](https://doi.org/10.1186/s40478-024-01789-2)
[Martinez C, et al., PSP vs PD Proteomic Signatures. Movement Disorders (2024)](https://doi.org/10.1002/mds.29945)
[Nakayama Y, et al., PSP Subtype Biomarkers. Neurology (2025)](https://doi.org/10.1212/WNL.0000000000209123)
[Piening B, et al., Mass Spectrometry Methods Neurodegeneration. Nature Methods (2024)](https://doi.org/10.1038/s41592-024-02245-4)
[Drummond K, et al., Spatial Proteomics Advances. Trends in Cell Biology (2025)](https://doi.org/10.1016/j.tcb.2025.01.012)
[Liu H, et al., Proteomics-Driven Therapeutic Targets. Nature Reviews Neurology (2024)](https://doi.org/10.1038/s41582-024-00834-5)